Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

April 18, 2024

— Application allowed with broad method claims that are Orange Book-listable —

— Once issued, this will be Evofem’s fifth patent covering Hormone-Free “In the Moment” Contraceptive Phexxi in the United States —

Read more at prnewswire.com

Related news for (EVFM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.